latest update:
[TrialBase DB]

trial summary · NCT06820723

A Mechanistic Study to Assess a Single Dose of CYB003 in Participants With Depression and Anxiety

A Randomized, Double-Blind, Placebo-Controlled Mechanistic Study to Assess a Single Oral Dose of CYB003 in Participants With Major Depressive Disorder (MDD) and Moderate to Severe Anxiety

Trial record from the TrialBase DB dataset, status RECRUITING, condition Depression, sponsored by Ohio State University. Facts below are exported values from the current release, not inferred or edited prose.

registry NCT06820723phase PHASE2enrollment 40start 2026-11-01

Summary

The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.

The goal of this study is to learn how psychedelics may help symptoms of depression and anxiety. Participants with major depressive disorder experiencing symptoms of depression and anxiety will receive one dose of either a drug related to psilocybin or a placebo. Assessments include interviews, self-report questionnaires, EEG and fMRI to measure symptoms and brain function.

Source record: https://clinicaltrials.gov/study/NCT06820723

Facts

registry idNCT06820723
primary registryclinicaltrials-gov
recruitment statusRECRUITING
phasePHASE2
study typeINTERVENTIONAL
lead conditionDepression
sponsorOhio State University
sponsor classOTHER
enrollment40
start date2026-11-01
primary completion2028-11
completion2028-11
results postednot reported

Conditions

  • Depression
  • Anxiety
  • Major Depressive Disorder

Interventions

  • CYB003
  • Placebo

Countries

  • United States

Intervention types: DRUG

Work with this record